Hew Chee Yee, McElvenny Damien M, Onwudike Madu
Manchester University NHS Foundation Trust, Manchester, UK.
Centre for Occupational and Environmental Health, University of Manchester, Manchester, UK; Research Group, Institute of Occupational Medicine, Edinburgh, UK.
J Vasc Surg Venous Lymphat Disord. 2025 Jan;13(1):101963. doi: 10.1016/j.jvsv.2024.101963. Epub 2024 Aug 22.
Several studies have shown that, in the short term, treatment outcomes following endothermal ablation of varicose veins without the prescription of post procedural compression are not inferior to outcomes when compression is routinely prescribed. This follow-up to our randomized controlled trial (RCT) published in 2020 explores whether the non-inferiority persists into the medium to long term.
All 94 patients from the RCT were recalled at 27 months after their initial radiofrequency ablation (RFA) procedure. The procedural details, randomization, and inclusion and exclusion criteria were described in the original RCT paper. Consent was obtained for further venous duplex ultrasound scan at 27 to 61 months after the initial procedure. The successful target vein closure at this juncture represented our primary outcome. Secondary outcomes include disease severity, measured using the Aberdeen Varicose Vein Severity Score (AVSS) and the Revised Venous Clinical Severity Score (RVCSS), post-procedural pain measured using Likert scale, and number of days taken for patients to return to work or normal activities.
Thirty-one of 48 patients (64.6%) in the compression group and 29 of 46 patients (63%) in the no-compression group were evaluated. The mean duration of follow-up was 43 and 42 months in the compression and no-compression group, respectively. The target vein occlusion rate evaluated at this longer-term follow up were 80.7% and 79.3% in the compression and no-compression groups, respectively. There was no significant difference between the two groups (P = .37). Secondary outcomes of quality of life and disease severity measured using AVSS and RVCSS showed no significant difference between the two groups (post-procedural AVSS mean score 5.2 in the compression group vs 8.3 in the no-compression group [95% confidence interval (CI), -7.3 to 1.1; P = .14]; post-procedural RVCSS mean score 1.5 in the compression group vs 1.8 in the no-compression group [95% CI, -1.1 to 0.7; P = .59]). Patient satisfaction was similar in both groups (mean score 6.4 in the compression group vs 5.9 in the no-compression group [95% CI, -0.22 to 1.17; P = .18]), and the number of days taken for patients to return to work were also comparable (mean of 11.9 days in the compression group vs 12.6 days in the no-compression group [95% CI, -7.7 to 6.2; P = .83]).
This study provided some evidence to support no additional benefit of compression use after RFA at a longer term follow-up of 3 years. However, larger, suitably powered studies would be beneficial to confirm this.
多项研究表明,短期内,在不常规开具术后加压治疗处方的情况下进行静脉曲张内热消融治疗的效果,并不逊于常规开具加压治疗处方时的效果。对我们于2020年发表的随机对照试验(RCT)的此次随访,探究了这种非劣效性在中长期是否依然存在。
RCT中的所有94例患者在首次射频消融(RFA)术后27个月被召回。原始RCT论文中描述了手术细节、随机分组情况以及纳入和排除标准。在首次手术后27至61个月,征得患者同意进行进一步的静脉双功超声扫描。此时目标静脉成功闭合为我们的主要结局。次要结局包括使用阿伯丁静脉曲张严重程度评分(AVSS)和修订的静脉临床严重程度评分(RVCSS)衡量的疾病严重程度、使用李克特量表测量的术后疼痛,以及患者恢复工作或正常活动所需的天数。
对加压组48例患者中的31例(64.6%)和非加压组46例患者中的29例(63%)进行了评估。加压组和非加压组的平均随访时间分别为43个月和42个月。在此次长期随访中评估的目标静脉闭塞率,加压组和非加压组分别为80.7%和79.3%。两组之间无显著差异(P = 0.37)。使用AVSS和RVCSS衡量的生活质量和疾病严重程度的次要结局,两组之间无显著差异(术后AVSS加压组平均评分为5.2,非加压组为8.3 [95%置信区间(CI),-7.3至1.1;P = 0.14];术后RVCSS加压组平均评分为1.5,非加压组为1.8 [95% CI,-1.1至0.7;P = 0.59])。两组患者的满意度相似(加压组平均评分为6.4,非加压组为5.9 [95% CI,-0.22至1.17;P = 0.18]),患者恢复工作所需的天数也相当(加压组平均为11.9天,非加压组为12.6天 [95% CI,-7.7至6.2;P = 0.83])。
本研究提供了一些证据,支持在3年的长期随访中,RFA术后使用加压治疗并无额外益处。然而,进行更大规模、有足够效力的研究将有助于证实这一点。